keyword
MENU ▼
Read by QxMD icon Read
search

Medullary thyroid cancer

keyword
https://www.readbyqxmd.com/read/28729773/is-new-american-thyroid-association-risk-classification-for-hereditary-medullary-thyroid-carcinoma-applicable-to-chinese-patients-a-single-center-study
#1
Xiwei Zhang, Dangui Yan, Junyi Wang, Hanfeng Wan, Yongxia Zhang, Yabing Zhang, Yuqin He, Wensheng Liu, Bin Zhang
OBJECTIVE: The American Thyroid Association (ATA) proposed a new risk classification for hereditary medullary thyroid carcinoma (MTC) in 2015. This study aimed to assess whether the new guidelines are suitable for the Chinese population, and reported our experience on prophylactic thyroidectomy. METHODS: A total of 73 patients from 22 families were screened as rearranged during transfection (RET) mutation carriers from 2010 to 2016 in Cancer Hospital, Chinese Academy of Medical Science; the medical history for each patient was collected...
June 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28710706/synchronous-and-metastatic-papillary-and-follicular-thyroid-carcinomas-with-unique-molecular-signatures
#2
Vincent Cracolici, Ibro Mujacic, Sabah Kadri, Mir Alikhan, Nifang Niu, Jeremy P Segal, Lauren E Rosen, David H Sarne, Adam Morgan, Samy Desouky, Nicole A Cipriani
Despite the relatively high prevalence of thyroid cancer, the occurrence of multiple synchronous, distinct subtypes of primary thyroid carcinoma is uncommon. The incidental finding of papillary thyroid microcarcinoma in a gland with a biologically relevant follicular or medullary carcinoma is more frequent than the synchronous occurrence of multiple clinically significant carcinomas. We report a case of synchronous papillary and follicular thyroid carcinomas metastatic to lymph node and bone, respectively. Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis...
July 14, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28698976/medullary-thyroid-cancer-clinical-characteristics-and-new-insights-into-therapeutic-strategies-targeting-tyrosine-kinases
#3
REVIEW
Sadegh Rajabi, Mehdi Hedayati
Medullary thyroid carcinoma (MTC) is a hyperplasia of thyroid C-cells, accounting for 5-10% of all thyroid cancers. MTCs may appear as sporadic or hereditary forms, and several molecules and signaling pathways have been found to function defectively in MTC cells. Tyrosine kinases are the most well-studied molecules that have abnormal function in these tumor cells. Due to their limited response, chemotherapeutic agents and radiation therapy are not effective in treating patients with advanced metastatic MTC...
July 11, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28687563/axitinib-treatment-in-advanced-rai-resistant-differentiated-thyroid-cancer-dtc-and-refractory-medullary-thyroid-cancer-mtc
#4
Jaume Capdevila, Jose Manuel Trigo, Javier Aller, Jose Luis Manzano, Silvia Garcia-Adrian, Carles Zafon, Oscar Reig, Uriel Bohn, Teresa Ramon Y Cajal, Manuel Duran, Beatriz Gonzalez-Astorga, Ana Lopez-Alfonso, Javier Medina, Ignacio Porras, Juan Jose Reina, Nuria Palacios, Enrique Grande, Elena Cillan, Ignacio Matos, Juan Jose Grau
BACKGROUND: Axitinib, an antiangiogenic multikinase inhibitor (MKI) was evaluated in the compassionate-use-program in Spain (October 2012-November 2014). MATERIALS AND METHODS: 47 patients with advanced radioactive iodine-refractory differentiated thyroid cancer (DTC, n=34) or medullary thyroid cancer (MTC, n=13) with documented disease progression were treated with axitinib 5 mg bid. The primary efficacy endpoint was overall response rate (ORR) by RECIST v1.1. Progression-free survival (PFS) and adverse events (AEs) were secondary objectives...
July 7, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28687188/-oral-and-dental-expression-of-thyroid-diseases
#5
Jean-Louis Wémeau, Christine Do Cao, Miriam Ladsous
Oral disorders were observed in children with congenital hypothyroidism, lately apparent because of difficulties of feeding, swallowing disorders, and macroglossia. Macroglossia was also a component of the severe acquired myxedema, particularly observed in hypothyroidism related to autoimmune atrophic thyroiditis beyond menopause. Lingual ectopy in children and adults could determine respiratory gene or swallowing difficulties, and were detectable by visual examination and the endobuccal touch. Expression of these events was completely minimized since the neonatal screening of congenital hypothyroidism, also by the common practice in adults of serum TSH determinations...
July 4, 2017: La Presse Médicale
https://www.readbyqxmd.com/read/28683235/prognostic-variables-affecting-primary-treatment-outcome-for-medullary-thyroid-cancer
#6
Suhael Momin, Deborah Chute, Brian Burkey, Joseph Scharpf
OBJECTIVE: Identifying prognostic risk factors and determining the efficacy of common surgical treatments is critical to determine optimal treatment strategies for patients with medullary thyroid carcinoma (MTC). The objective of this study was to review a contemporary institutional experience with medullary thyroid carcinoma primary treatment with two goals: to identify prognostic factors that affect survival and to study the effect of neck dissection on those outcomes. METHODS: This study is a retrospective case series of patients with MTC who underwent at least a total thyroidectomy with curative intent...
July 6, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28680210/incidentally-detected-thyroid-follicular-neoplasm-on-somatostatin-receptor-imaging-and-post-therapy-scan
#7
Apurva Sood, Harpreet Singh, Ashwani Sood, Rajender Kumar Basher, Bhagwant Rai Mittal
Peptide receptor radionuclide therapy (PRRT) either using Lu-177 or Y-90 peptide radiopharmaceuticals has emerged as promising treatment modality in patients with inoperable metastatic neuroendocrine tumour (NET) including medullary thyroid cancer, because of overexpression of somatostatin receptor 2 (sstr-2) on these cells. The several investigators have used PRRT in non-iodine avid differentiated thyroid cancer patients with limited success, where other treatment modalities have failed, probably due to faint sstr-2 expression in these lesions...
July 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28676824/prognostic-impact-of-mir-224-and-ras-mutations-in-medullary-thyroid-carcinoma
#8
Elisabetta Cavedon, Susi Barollo, Loris Bertazza, Gianmaria Pennelli, Francesca Galuppini, Sara Watutantrige-Fernando, Simona Censi, Maurizio Iacobone, Clara Benna, Federica Vianello, Stefania Zovato, Davide Nacamulli, Caterina Mian
Little is known about the function of microRNA-224 (miR-224) in medullary thyroid cancer (MTC). This study investigated the role of miR-224 expression in MTC and correlated it with mutation status in sporadic MTCs. A consecutive series of 134 MTCs were considered. Patients had a sporadic form in 80% of cases (107/134). In this group, REarranged during transfection (RET) and rat sarcoma (RAS) mutation status were assessed by direct sequencing in the tumor tissues. Quantitative real-time polymerase chain reaction was used to quantify mature hsa-miR-224 in tumor tissue...
2017: International Journal of Endocrinology
https://www.readbyqxmd.com/read/28662997/next-generation-immunohistochemistry-emerging-substitutes-to-genetic-testing
#9
REVIEW
Juliana Andrici, Anthony J Gill, Jason L Hornick
The identification of at-risk kindreds facilitates screening and risk reduction strategies for patients with hereditary cancer predisposition syndromes. Recently, immunohistochemistry (IHC) has emerged as a cost-effective strategy for detecting or inferring the presence of mutations in both tumors and the germline of patients presenting with tumors associated with hereditary cancer predisposition syndromes. In this review we discuss the use of novel IHC markers, including PRKAR1A, β-catenin, SDHB, fumarate hydratase and 2SC, HRASQ61R, BAP1, parafibromin and glucagon, which have either established applications or show promise for surgical pathologists to complement morphological or clinical suspicion of hereditary cancer predisposition syndromes...
June 27, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28639308/discovery-of-novel-wtret-and-v804mret-inhibitors-from-hit-to-lead
#10
Luca Mologni, Martina Dalla Via, Adriana Chilin, Manlio Palumbo, Giovanni Marzaro
Oncogenic activation of the RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma and non-small cells lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wtRET and its mutants (e.g. V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor (69) endowed with 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound...
June 22, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28636708/improvement-of-tnm-staging-for-medullary-thyroid-cancer
#11
Quan-Yang Duh, Jessica E Gosnell
No abstract text is available yet for this article.
June 21, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28636692/rethinking-the-current-american-joint-committee-on-cancer-tnm-staging-system-for-medullary-thyroid-cancer
#12
Mohamed Abdelgadir Adam, Samantha Thomas, Sanziana A Roman, Terry Hyslop, Julie A Sosa
Importance: Controversy exists around the American Joint Committee on Cancer (AJCC) TNM staging system for medullary thyroid cancer (MTC). Because of the rarity of the disease and limited available data, the staging system for MTC has been largely extrapolated from staging for differentiated thyroid cancer. Objectives: To evaluate how well the current (seventh and eighth editions) AJCC TNM staging system correlates with survival for patients with MTC and to suggest a possible revision...
June 21, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28635560/sorafenib-in-japanese-patients-with-locally-advanced-or-metastatic-medullary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma
#13
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan even though vandetanib for MTC, and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). We conducted an uncontrolled, open-label, multicenter, single-arm, phase 2 clinical study to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC...
June 21, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28634649/assessment-of-cabozantinib-treatment-on-qt-interval-in-a-phase-3-study-in-medullary-thyroid-cancer-evaluation-of-indirect-qt-effects-mediated-through-treatment-induced-changes-in-serum-electrolytes
#14
Dale R Miles, Steven A Lacy, David R Wada, Steve Milwee, Yifah Yaron, Linh T Nguyen
PURPOSE: This study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC). METHODS: Electrocardiogram (12-lead ECG) measurements were obtained at screening, and at pre-dose, and 2, 4, and 6 h post-dose on Days 1 and 29 in a phase 3 study in patients with MTC treated with cabozantinib (140 mg/day). Central tendency analyses were conducted on baseline-corrected QTc values. Linear and nonlinear mixed-effects models were used to evaluate potential factors affecting the QTc interval, including serum electrolytes, patient demographics, and cabozantinib concentration...
June 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28633552/cabozantinib-for-the-treatment-of-kidney-cancer
#15
REVIEW
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator...
July 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28621690/ratio-of-positive-lymph-nodes-the-prognostic-value-in-stage-iv-thyroid-cancer
#16
Tingyin Jiang, Chunling Huang, Yuan Xu, Yingrui Su, Guanjie Zhang, Long Xie, Liqun Huang, Shuchun You, Jinshun Zha
To assess the prognostic value of lymph node ratio (LNR) in patients with stage IV thyroid cancer based on the Surveillance, Epidemiology, and End Results (SEER) database. A total of 4,940 eligible patients were included for the analysis. Kaplan-Meier survival analysis and Cox proportional hazard regression were used to reveal the effect of LNR on overall survival (OS) and disease specific survival (DSS). The optimal cut-off value of LNR for predicting OS and DSS was determined by the time-dependent Receiver Operating Characteristic analysis...
June 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28614009/the-combined-use-of-calcitonin-doubling-time-and-18-f-fdg-pet-ct-improves-prognostic-values-in-medullary-thyroid-carcinoma-the-clinical-utility-of-18-f-fdg-pet-ct
#17
Ji H Yang, Cléber P Camacho, Susan C Lindsey, Flavia O F Valente, Danielle M Andreoni, Lilian Y Yamaga, Jairo Wagner, Rosa Paula M Biscolla, Rui M B Maciel
OBJECTIVE: Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand, positron emission tomography with fluorine-18 fluorodeoxyglucose ((18)F-FDG PET/CT) shows an increased rate of detection with high blood tumor marker levels in several cancers. This study aims to analyze the ability of (18)F-FDG PET/CT to determine prognosis in the followup of patients with MTC. METHODS: Medical records of 17 patients with MTC who underwent (18)F-FDG PET/CT were analyzed retrospectively...
June 14, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28610401/oncogenesis-of-thyroid-cancer
#18
Enas Younis
Thyroid neoplasms encompass a variety of lesions that range from benign adenomas to malignancies. These latter can be well-differentiated, poorly differentiated or undifferentiated (anaplastic) carcinomas. More than 95% of thyroid cancers are derived from thyroid follicular cells, while 2-3% (medullary thyroid cancers, MTC) originate from calcitonin producing C-cells. Over the last decade, investigators have developed a clearer understanding of genetic alterations underlying thyroid carcinogenesis. A number of point mutations and translocations are involved, not only in its tumorigenesis, but also as have potential use as diagnostic and prognostic indicators and therapeutic targets...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28609830/medullary-thyroid-carcinoma-in-men2a-ata-moderate-or-high-risk-ret-mutations-do-not-predict-disease-aggressiveness
#19
Rachel K Voss, Lei Feng, Jeffrey E Lee, Nancy D Perrier, Paul H Graham, Samual M Hyde, Frances Nieves-Munoz, Maria E Cabanillas, Steven G Waguespack, Gilbert J. Cote, Robert F Gagel, Elizabeth G Grubbs
Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. Objective: To determine if high-risk RET mutations are more aggressive Design: Retrospective cohort study utilizing institutional MEN2 registry Setting: A tertiary cancer care center Patients: Those with MTC and moderate- or high-risk germline RET mutation...
May 9, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28605116/phaeochromocytoma-in-multiple-endocrine-neoplasia-type-2-ret-codon-specific-penetrance-and-changes-in-management-during-the-last-four-decades
#20
L Mucha, G Leidig-Bruckner, K Frank-Raue, Th Bruckner, M Kroiss, F Raue
OBJECTIVES: We describe phaeochromocytoma (phaeo) penetrance in multiple endocrine neoplasia type 2 (MEN2) according to RET protooncogene-specific mutations and report changes in phaeo diagnosis and management from 1968 to 2015. DESIGN: This retrospective chart review included 309 MEN2 patients from one specialized ambulatory care centre. Phaeo patients were categorized by diagnosis date: early, 1968-1996, n=40, and recent, 1997-2015, n=45. RESULTS: Phaeochromocytoma was diagnosed in 85/309 patients with RET mutations in the following exons (phaeos/all carriers, %): exon 11 (56/120, 46...
June 12, 2017: Clinical Endocrinology
keyword
keyword
4630
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"